ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 19-11-2024
₹ 40.09
▲0.8%
1D
Inception Returns
24.4%
/yr
About ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is an equity fund. This fund was started on 12 July, 2018. The fund is managed by Dharmesh Kakkad. The fund could potentially beat inflation in the long-run.
Key Parameters
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has ₹5024 Cr worth of assets under management (AUM) as on Oct 2024 and is more than category average.
- The fund has an expense ratio 1.1.
Returns
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has given a CAGR return of 24.41% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 49.20%, 24.29% and 31.28% respectively.
Holdings
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd, Lupin Ltd, Aurobindo Pharma Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
4606 people have invested ₹ 5Cr in ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth in the last three months
INDmoney Rank for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Larger AUM within category
No bad points found for this fund.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth Overview
| Expense ratio | 1.09% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹5024 Cr |
| Inception Date | 12 July, 2018 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 49.46% |
| STCG | Redeeming before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (19-Nov-24)
Fund Distribution
as on (31-Oct-24)
Large cap
41.9%
Small cap
32.4%
Mid cap
22.7%
Sector Allocation
Health
97.7%
Basic Materials
1.3%
Financial Services
0.9%
All changes are between Aug'24 and Oct'24
- This fund’s returns stands at -0.98% whereas the fund’s underlying benchmark Nifty 500 returns stands at -6.52% as on Oct'24
- This fund outperformed Nifty 500 by 5.54% in Oct'24
- AUM of the fund stands at 5K Cr as of Oct'24
- AUM increased by 36.5 Cr between Oct'24 and Sep'24
Top Stocks bought last month
Cipla Ltd's allocation increased from 6.52% to 8.07%
Zydus Lifesciences Ltd's allocation increased from 2.15% to 2.93%
Aarti Drugs Ltd's allocation increased from 0.26% to 0.83%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 15.45 % to 14.35 %
Dr Reddy's Laboratories Ltd's allocation decreased from 9.63 % to 9.03 %
Lupin Ltd's allocation decreased from 4.64 % to 4.59 %
Small Cap allocation has gone up from 30.6% to 32.4%
Mid Cap allocation has gone up from 21.6% to 22.7%
Large Cap allocation has gone up from 41.8% to 41.9%
Cash allocation has gone down from 5.1% to 2.1%
Top 3 Sectors in October were Health, Financial Services & Basic Materials
Oct'24
Health
98%
Basic Materials
1%
Financial Services
Sep'24
Health
96%
Financial Services
2%
Basic Materials
2%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Wockhardt Ltd | 11.1% |
Loading...
We are taking more time than usual
Dharmesh Kakkad
Fund Manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth, since 2 May 2020
Top funds managed
Fund House
ICICI Prudential Asset Management Company Limited
Total Schemes
Total AUM
₹8.35L Cr
as on 31-Oct-2024
Address
ICICI Prudential Asset Mgmt.Company Limited,3rd Floor, Hallmark Business Plaza,,Sant Dyaneshwar Marg,,Bandra (East)
Phone
+912226428000
Website
investor.helpdesk@hdfcbank.com
Mutual Fund Insights
Over the last 6 months, this fund has experienced a 31.0% growth in AUM moving from 3.83K Cr to 5.02K Cr.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 52.89% return, outperforming this fund by 3.69%.
Over the last 6 months, this fund has increased expense ratio by 4.8% moving from 1.04 to 1.09.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 32.68% return, outperforming this fund by 1.4% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.09% which is lower than the category average expense ratio of 1.39%.
In the last 3 years, this fund has outperformed all funds in its category.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 24.41% since inception which is less than its category average return of 24.96%
Fund Allocations
This fund has an allocation of 97.87% in Equity, 0% in Debt and 2.13% in Cash related instruments
AUM size ₹5024 Cr
This fund has AUM of ₹5024 Cr which is more than its category average of ₹ 2001 Cr
Expense Ratio 1.09%
This fund has an expense ratio of 1.09% which is less than its category average expense ratio of 1.33%
Frequently Asked Questions for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
The current NAV of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is ₹40.09 as on 19-Nov-2024.
Existing (Absolute + CAGR) as on 19-Nov-2024.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -4.04% | -4.05% |
6 Month Returns | 22% | 22% |
1 Year Returns | 49.2% | 49.2% |
3 Years Returns | 92% | 24.29% |
5 Years Returns | 289.98% | 31.28% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.09% as on October 2024
₹5024 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(14.35%), Dr Reddy's Laboratories Ltd(9.03%), Cipla Ltd(8.07%), Lupin Ltd(4.59%), Aurobindo Pharma Ltd(4.57%) as on October 2024
Health(95.66%), Basic Materials(1.32%), Financial Services(0.89%) as on October 2024
The alpha ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 4.83 | 4.19 | 4.27 |
As on October 2024
The alpha for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 0.94 | 0.9 | 0.96 |
As on October 2024
The Beta for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 3.32 | 1.19 | 1.3 |
As on October 2024
The sharpe ratio for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 13.77 | 14.94 | 19.09 |
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 2.49 as on October 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.91 as on October 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Dharmesh Kakkad is the fund manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
The Exit load of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is 1%